Personal information

Websites & social links

SDU profile page

Other IDs

Scopus Author ID: 57226525377
Scopus Author ID: 57226525377

Countries

Denmark

Activities

Collapse all

Employment (5)

SDU: N/A, DK

Employment
Source: check_circle
University of Southern Denmark

Odense Universitetshospital: Odense, Syddanmark, DK

2022-01-01 to present | PhD student (Department of Hematology)
Employment
Source: Self-asserted source
Mette Bøegh Levring

Odense Universitetshospital: Odense, Syddanmark, DK

2021-10-01 to 2021-12-31 | Doctor (Department of Infectious diseases)
Employment
Source: Self-asserted source
Mette Bøegh Levring

Odense Universitetshospital: Odense, DK

2020-09-01 to 2021-08-31 | Doctor (Dept. of Clinical Immunology)
Employment
Source: Self-asserted source
Mette Bøegh Levring

Odense Universitetshospital: Odense, DK

2018-09-01 to 2019-10-01 | Doctor (Dept of Hematology)
Employment
Source: Self-asserted source
Mette Bøegh Levring

Education and qualifications (1)

Syddansk Universitet: Odense, Syddanmark, DK

2011-02-01 to 2017-06-01 | cand.med. (MD)
Education
Source: Self-asserted source
Mette Bøegh Levring

Works (9)

Do osteolytic fractures in multiple myeloma heal? Applied methods in a study of vertebral fracture biopsies of multiple myeloma patients

NMSG meeting, Göteborg, Sweden, 11/09/2024
2024 | Conference abstract | Author
SOURCE-WORK-ID:

7f45cfd2-2111-4b88-b24b-fa01b83d6671
Contributors: Mette Bøegh Levring
Source: check_circle
University of Southern Denmark

Do osteolytic fractures in multiple myeloma heal? Preliminary findings from a study of 24 bone biopsies from vertebral fractures of multiple myeloma patients

The Danish Bone Research Workshop , 08/03/2024
2024-03-08 | Conference abstract | Author
SOURCE-WORK-ID:

deb7be1b-93d6-400a-912f-b7467f230e9e
Contributors: Mette Bøegh Levring
Source: check_circle
University of Southern Denmark

The real-world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies

eJHaem
2023-11 | Journal article | Author
DOI: 10.1002/jha2.774
SOURCE-WORK-ID:

484c3f56-8943-4737-ac51-433f60e655a7

PMID: 38024635
Contributors: Agoston Gyula Szabo; Jonathan Thorsen; Katrine Fladeland Iversen; Mette Bøegh Levring; Carsten Helleberg; Emil Hermansen; Søren Thorgaard Bønløkke; Katrine Nielsen; Elena Manuela Teodorescu; Eva Kurt et al.
Source: check_circle
University of Southern Denmark

Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease

Cancers
2023-11-25 | Journal article
DOI: 10.3390/cancers15235585
Contributors: Martin Johansen; Mette Bøegh Levring; Kasper Stokbro; Marta Diaz-delCastillo; Abdul Ahad Khan; Line Adsbøll Wickstroem; Michael Tveden Gundesen; Ida Bruun Kristensen; Charlotte Guldborg Nyvold; Mikkel Østerheden Andersen et al.
Source: check_circle
Crossref
grade
Preferred source (of 3)‎

SARS‐CoV‐2 antibody kinetics in blood donors with a previously positive SARS‐CoV‐2 antibody test within a seroprevalence survey

Journal of Medical Virology
2022-04 | Journal article
DOI: 10.1002/jmv.27486
Contributors: Mette B. Levring; Dorte K. Holm; Anna C. Nilsson; Joschka M. Bauer; Iben S. Jensen; Jesper R. Davidsen; Line D. Rasmussen; Ulrik Sprogøe; Søren T. Lillevang
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

The clinical course and life expectancy of patients with multiple myeloma who discontinue their first daratumumab-containing line of therapy

American Journal of Hematology
2022-03 | Other | Author
DOI: 10.1002/ajh.26449
SOURCE-WORK-ID:

035148e8-81ab-4df0-9c3e-3f92d4c8d59e

PMID: 34967035
EID:

2-s2.0-85122077675
Contributors: Agoston Gyula Szabo; Jonathan Thorsen; Katrine Fladeland Iversen; Mette Bøegh Levring; Birgitte Preiss; Carsten Helleberg; Marie Fredslund Breinholt; Emil Hermansen; Lise Mette Rahbek Gjerdrum; Søren Thorgaard Bønløkke et al.
Source: check_circle
University of Southern Denmark

Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients

Hematological Oncology
2021 | Journal article
DOI: 10.1002/hon.2906
EID:

2-s2.0-85111847498

Part of ISSN: 10991069 02780232
Contributors: Højholt, K.L.; Gregersen, H.; Szabo, A.G.; Klausen, T.W.; Levring, M.B.; Preiss, B.; Helleberg, C.; Breinholt, M.F.; Hermansen, E.; Rahbek Gjerdrum, L.M. et al.
Source: Self-asserted source
Mette Bøegh Levring via Scopus - Elsevier
grade
Preferred source (of 2)‎

The Clinical Course and Life Expectancy of Patients with Multiple Myeloma Who Discontinue Their First Daratumumab-Containing Line of Therapy

Blood
2021-11 | Conference abstract | Author
DOI: 10.1182/blood-2021-152070
SOURCE-WORK-ID:

437cf1e2-134d-481c-8aba-e15470c9814a
Contributors: Agoston Gyula Szabo; Jonathan Thorsen; Katrine Fladeland Iversen; Mette Bøegh Levring; Birgitte Preiss; Carsten Helleberg; Marie Fredslund Breinholt; Emil Hermansen; Lise Mette Rahbek Gjerdrum; Søren Bønløkke et al.
Source: check_circle
University of Southern Denmark

The real-world outcomes of multiple myeloma patients treated with daratumumab.

PloS one
2021-10-13 | Journal article
DOI: 10.1371/journal.pone.0258487
PMID: 34644367
PMC: PMC8513840
Source: Self-asserted source
Mette Bøegh Levring
grade
Preferred source (of 2)‎
How many people are using ORCID?